Printer Friendly

ADDITIONAL INFORMATION ON AUSTRIAN TOPICAL PAIN TRIALS

 MISSISSAUGA, Ontario, Sept. 8 /PRNewswire/ -- Additional results on the effectiveness of HYAL-AT2101, Hyal Pharmaceutical Corporation's (NASDAQ-NMS: HYALF) topical pain formulation were presented this week by Professor K. Chlud, at the International Ischia Days Seminar on Topical Therapy, Ischia, Poland. Professor Chlud provided additional information and details on previously reported studies (Jan. 5, 1993). His findings showed that in 18 patients with acute pain due to osteoarthritis (OA) of the knee with effusion, and in 17 patients with acute pain due to tender points in the trapecius muscle there was a significantly higher level of pain threshold measurement (PTM) performance in the study group versus the control group (P less than 0.001). PTM is a quantitative measure of pain. Although a group of six patients with rheumatoid arthritis of the knee were also evaluated, the small sample size prohibited drawing any conclusions.
 Dr. Chlud concluded that, "The analgesia due to diclofenac and hyaluronic acid (HYAL-AT2101) was more intensive and lasted longer as compared to control medication (diclofenac gel without hyaluronic acid)."
 Results are consistent with previous findings and support the company's growing evidence that Hyal's proprietary drug delivery technology is able to significantly improve the effectiveness of one of the world's most widely prescribed anti-inflammatory/analgesic drugs.
 Hyal specializes in the development and world wide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronic Acid based drug delivery technology. Hyal is currently conducting Phase III clinical trials at 14 independent centers in Canada, the U.S., Australia and a number of European countries for its three lead products: HYAL-CT1101 for the treatment of basal cell carcinoma, HYAL-AT2101 for the topical treatment of pain and HYAL-AV2201 for the intravenous treatment of moderate to severe pain.
 Hyal Pharmaceutical Corporation's shares are traded on the Toronto Stock Exchange under the trading Symbol HPC and on NASDAQ National Market system under the trading symbol HYALF.
 -0- 9/8/93
 /CONTACT: Samuel S. Asculai, president and CEO, 416-366-4863, or David W. Harper, vice president-development, 416-366-4863, both of Hyal Pharmaceutical Corporation; or Diane Perry, 212-661-8030, or Kathy Brunson, 312-266-7800, both of the Financial Relations Board/
 (HYALF)


CO: Hyal Pharmaceutical Corporation ST: Ontario IN: MTC SU:

SM -- NY020 -- 9720 09/08/93 10:24 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 8, 1993
Words:367
Previous Article:MTC ELECTRONIC TECHNOLOGIES REPORTS MILESTONES REACHED IN PROGRESS OF TELECOMMUNICATIONS JOINT VENTURES IN CHINA
Next Article:MITCHELL ENERGY BOOSTS DRILLING BUDGET
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters